{
    "clinical_study": {
        "@rank": "121205", 
        "arm_group": [
            {
                "arm_group_label": "TACE&Stents", 
                "arm_group_type": "Experimental", 
                "description": "chemoembolization combined with endovascular stents and iodine-125 seed strand implantation"
            }, 
            {
                "arm_group_label": "TACE", 
                "arm_group_type": "Active Comparator", 
                "description": "Transartery chemoembolisation\uff08TACE\uff09 by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether TACE combined endovascular stent\n      implantation confers a survival benefit over TACE alone."
        }, 
        "brief_title": "Combination Treatment for Advanced Liver Cancer", 
        "condition": [
            "Hepatocellular Carcinoma", 
            "Hepatic Portal Vein Tumor Invasion"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  (1) Hepatocellular carcinoma(HCC) diagnosis confirmed by needle biopsy or by two\n             coincidental imaging techniques associated with increased \u03b1-fetoprotein according to\n             the American Association for the Study of Liver Diseases (AASLD) guidelines and\n             contrast-enhancing tumour thrombus within the main portal vein and one of the\n             first-order branch on CT or MRI;\n\n          -  (2) Child-Pugh classification grade A or B\uff1b\n\n          -  \uff083\uff09Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.\n\n        Exclusion Criteria:\n\n          -  advanced liver disease (bilirubin levels >3 mg/dL, ASTor ALT >5 \u00d7 upper limit of\n             normal)\uff1b\n\n          -  Tumor invade the Inferior Vena Cava, extrahepatic spread;\n\n          -  contraindications for doxorubicin or oxaliplatin chemotherapy;\n\n          -  any contraindication to an arterial procedure such as impaired clotting tests\n             (platelet count below 50 \u00d7 109/L or prothrombin activity below 50 %);\n\n          -  renal failure,cardiac ejection fraction <50 %) or end-stage disease\uff1b\n\n          -  patients who were not capable of cooperation during the procedure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149771", 
            "org_study_id": "ZS-IR 2013"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TACE&Stents", 
                    "TACE"
                ], 
                "description": "Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.", 
                "intervention_name": "chemoembolization", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "TACE&Stents", 
                "description": "Bare stents implant within portal vein.", 
                "intervention_name": "endovascular stents implantation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "TACE&Stents", 
                "description": "Iodine-125 seed strand implant within portal vein.", 
                "intervention_name": "iodine-125 seed strand implantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Iodine", 
                "Cadexomer iodine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hepatocellular carcinoma", 
            "portal vein tumor thrombosis", 
            "stents", 
            "chemoembolization"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "522623124@qq.com", 
                "last_name": "Jianjun Luo, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Department of Interventional Radiology, Zhongshan Hospital, Fudan University"
            }, 
            "investigator": [
                {
                    "last_name": "Zhinping Yan, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jianjun Luo, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Transarterial Chemoembolisation (TACE) Combined With Endovascular Implantation of Bare Stent and Iodine-125 Seed Strand for the Treatment of Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis Versus TACE Alone", 
        "overall_contact": {
            "email": "522623124@qq.com", 
            "last_name": "Minjie Yang, MD", 
            "phone": "+8613818947653"
        }, 
        "overall_contact_backup": {
            "email": "yangminjie123@126.com", 
            "last_name": "Qinghui Yang, MD", 
            "phone": "+8613917628732"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Interventional Radiology, Zhongshan Hospital, Fudan University", 
                "last_name": "Zhinping Yan, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Interventional Radiology, Zhongshan Hospital, Fudan University", 
                "last_name": "Jianjun Luo, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: ZhongShan hospital Fudan Uinivercity"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Median survival time", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149771"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Zhongshan Hospital", 
            "investigator_full_name": "Zhiping Yan", 
            "investigator_title": "Prof.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Time to Disease Progression", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Shanghai Zhongshan Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Shanghai Municipal Science and Technology Commission", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shanghai Zhongshan Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}